- Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices. Reviews in neurological diseases. 2007 Article GET IT
Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group.
Multiple sclerosis (Houndmills, Basingstoke, England).
Times cited: 11